New drugs for the treatment of human African trypanosomiasis: research and development.
Chemotherapy of human African trypanosomiasis is problematic because of the high frequency of severe adverse events, the long duration and high cost of treatment, and an increasing number of treatment-refractory cases. New cost-efficient, easy-to-use drugs are urgently needed. Whereas basic research on potential drug targets is anchored in academia, the complex, highly regulated and very expensive process of preclinical and clinical drug development is almost exclusively in the hands of pharmaceutical companies. Jennifer Keiser, August Stich and Christian Burri here review, from the angle of industrial drug research and development, the past ten years of research activities at different stages of the development of trypanocidal drugs, and assess future prospects. The absence of compounds in clinical development Phases I-III indicates no new drugs will become available in the next few years.
Keiser
J
J
Swiss Tropical Institute, PO Box, CH-4002, Basel, Switzerland.
Stich
A
A
Burri
C
C
D000818:Animals; D004338:Drug Combinations; D005978:Glutathione / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D013095:Spermidine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D013830:Thiadiazoles / Q000494:pharmacology / Q000627:therapeutic use; D014344:Trypanocidal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D014345:Trypanosoma / Q000187:drug effects; D016833:Trypanosoma brucei rhodesiense / Q000187:drug effects; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D004338:Drug Combinations; D013830:Thiadiazoles; D014344:Trypanocidal Agents; C013378:megazol; C044809:trypanothione; D005978:Glutathione; D013095:Spermidine